Lasofoxifene

Target: This ligand targets estrogen receptors ERα/ESR1 and ERβ/ESR2 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for estrogen receptors ERα/ESR1 and ERβ/ESR2. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings estrogen receptors ERα/ESR1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• Estrogen Receptor PROTACs: Lasofoxifene can serve as a ligand warhead to recruit estrogen receptor (ER) proteins in PROTAC architectures. By coupling ER-binding moieties to E3 ligase recruiters, researchers can probe ER-dependent ubiquitination and degradation, enabling targeted interrogation of ER signaling networks and downstream transcriptional outputs in cellular models.

• ERα/ERβ Degradation Mapping: Using lasofoxifene-based binding elements, PROTAC designs can be optimized to distinguish degradation efficiencies across ERα and ERβ isoforms. This supports systematic studies of isoform-selective proteolysis, residence-time effects, and degradation kinetics, helping clarify how ligand engagement translates into ubiquitin–proteasome processing and altered gene regulation.

• Ligand-Dependent Degrader Profiling: Lasofoxifene’s pharmacology enables PROTAC comparisons that separate receptor engagement from degradation outcomes. Researchers can evaluate whether different linker lengths, geometries, or E3 ligase choices shift the balance between stabilization and productive ubiquitination, generating mechanistic insight into how PROTAC parameters govern target turnover and pathway rewiring.

• Mechanistic Ubiquitination Studies: Lasofoxifene-directed PROTACs can be used to investigate the molecular steps leading to ER degradation, including ternary complex formation, ubiquitin chain assembly, and proteasome dependence. Such studies often employ time-resolved degradation assays and ubiquitination readouts to define rate-limiting events and validate targeted protein degradation mechanisms.

Lasofoxifene is an estrogen receptor ligand scaffold that may support ER-directed PROTAC design. Linker placement should preserve the hydrophobic receptor-binding core and phenolic recognition element.

Structure: Lasofoxifene is a selective estrogen receptor ligand containing a tetrahydronaphthalene core, phenolic hydroxyl group, phenyl substituent, and pyrrolidinylethoxy aryl side chain. The rigid hydrophobic scaffold and basic tertiary amine side chain define its ER-binding geometry.

Reactivity: For ER-targeted PROTAC design, linker attachment may be explored through the phenolic hydroxyl or pyrrolidinylethoxy side-chain region depending on which vector preserves receptor binding. Alkyl, PEG, ether, carbonate, carbamate, or amide linkers can be paired with CRBN, VHL, or IAP ligands in appropriately designed analogs. The steroid-mimetic hydrophobic core and phenolic hydrogen-bonding pattern should be preserved unless SAR supports modification.